Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2020 · 10-Q
Revenue$8.85B$8.85B+9.6% vs Q3 2019 Net Income$1.23B$1.23B+28.3% vs Q3 2019 EPS Diluted$0.69$0.69+30.2% vs Q3 2019 Operating Income$1,495,000,000+24.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,570,000,000+1.5% Margins · derivedOperating margin16.9%+2.1 pt vs Q3 2019
Net margin13.9%+2.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end